The latest price target for aTyr Pharma (NASDAQ:ATYR) was reported by HC Wainwright & Co. on December 10, 2024. The analyst firm set a price target for $35.00 expecting ATYR to rise to within 12 months (a possible 944.78% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for aTyr Pharma (NASDAQ:ATYR) was provided by HC Wainwright & Co., and aTyr Pharma reiterated their buy rating.

There is no last upgrade for aTyr Pharma

There is no last downgrade for aTyr Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on December 10, 2024 so you should expect the next rating to be made available sometime around December 10, 2025.

While ratings are subjective and will change, the latest aTyr Pharma (ATYR) rating was a reiterated with a price target of $35.00 to $35.00. The current price aTyr Pharma (ATYR) is trading at is $3.35, which is out of the analyst’s predicted range.